Inflammatory immune cells can modulate activation of hepatic stellate cells (HSCs) and progression of liver fibrosis. Type 3 inflammation characterized by production of interleukin-17A (IL-17) and IL-22 by innate and adaptive immune cells is implicated in many inflammatory conditions of the gut and can be counteracted by regulatory T cells (T regs ), but its contribution to liver fibrosis is still poorly understood. Here, we evaluated the contribution of type 3 inflammation in liver fibrosis using clinical liver biopsies, in vitro stimulation of primary HSCs, and in vivo mouse models. We report dysregulated type 3 responses in fibrotic lesions with increased IL-17
INTRODUCTION
Chronic liver injury and inflammation induced by viral infections, toxins, and metabolic and autoimmune conditions lead to progressive fibrosis, cirrhosis, and liver cancer (1) . Transforming growth factor- (TGF-) signaling is the key fibrogenic signal that activates hepatic stellate cells (HSCs), the main producer of extracellular matrix in the liver, and is modulated by proinflammatory mediators such as cytokines that act on HSCs and liver immune cells (1) .
The inflammatory response can be divided into three types (2) . Type 1 inflammation, characterized by production of interleukin-1 (IL-1), IL-6, tumor necrosis factor- (TNF-), and interferon- (IFN-), is proinflammatory and correlates with liver inflammation but is antifibrogenic (3, 4) . Type 2 inflammation, characterized by production of IL-4, IL-5, IL-10, IL-13, IL-25, and IL-33, is associated with reduced hepatic inflammation but correlates with progression of liver fibrosis (4) . The current theory is that the imbalance between type 1 and type 2 inflammation is the major driver of fibrosis in the liver (1) . Type 3 inflammation is characterized by production of IL-17A, IL-17F, IL-22, and IL-26 produced by neutrophils, mast cells, group 3 innate lymphoid cells (ILC3), and T helper 17 (T H 17) and T H 22 cells (2) . Type 3 cytokines play an important physiological role in tissue homeostasis but can be pathogenic (5) . Dysregulated type 3 immunity is associated with abnormal tissue repair, chronic inflammatory diseases, and cancer in the gut and the lung (5) .
IL-17A has profibrogenic functions through recruitment of proinflammatory monocytes, increased production of TGF-, and enhanced TGF- responses in HSCs (6) (7) (8) (9) (10) . IL-22 is hepatoprotective during acute liver injury (11, 12) , but its function during chronic injury is controversial. Opposite effects of IL-22 were reported in the lung and the liver depending on the duration of injury and etiology (13) (14) (15) . IL-22 promotes liver cancer development in individuals with cirrhosis, which suggests that its protective function can be detrimental in the long term (16, 17) . The balance between IL-17A and IL-22 also contributes to pathogenesis, but the molecular mechanisms are unknown (15) . Thus, the role of type 3 inflammation in liver disease and fibrosis progression remains elusive.
Regulatory (FOXP3 hi CD4 + ) T cells (T regs ) dampen activation and pathogenesis of proinflammatory cells in several inflammatory conditions (18, 19) . The ratio between T regs and other inflammatory cells is one of the key determinants of the progression of inflammatory diseases (18) . IL-10, a cytokine that can be produced by T regs , induces apoptosis of activated HSC (20, 21) . It is therefore possible that T regs could limit fibrosis progression through the secretion of IL-10. However, T regs may have a dual role because they are enriched in fibrotic livers and may protect activated HSCs from natural killer (NK) cell-mediated killing, thus allowing them to achieve their full fibrogenic potential (22, 23) . During chronic liver injury, T regs induce aberrant B cell responses that may contribute to pathogenesis through the expression of CD40L (24) .
Here, we investigated the contribution of the type 3 cytokines IL-17A and IL-22 to the progression of liver fibrosis. Using primary human intrahepatic lymphocytes (IHLs) and HSCs, liver biopsy specimens, advanced microscopy, gene expression, and knockout (KO) mice, we observed that dysregulation of IL-17A 
RESULTS

Increased intrahepatic IL-17A and IL-22 is a common signature of advanced liver fibrosis
To investigate whether type 3 cytokines are implicated in liver fibrosis, we profiled the cytokines produced by IHLs from liver biopsies of patients with viral hepatitis (VH) and nonviral hepatitis (NVH) (table S1). A METAVIR score was used to stratify patients into moderate (F0-F2, n = 21) or advanced (F3-F4, n = 9) fibrosis. Because of the limited number of cells, IHLs were expanded in vitro and then polyclonally stimulated, and supernatants were used to quantify type 1 (IFN-, IL-6, and TNF-), type 2 (IL-4, IL-5, IL-9, IL-10, and IL-13), and type 3 (IL-17A, IL-17F, IL-21, and IL-22) cytokines using the LEGENDplex assay. Type 1 cytokines were predominantly produced by IHLs independent of etiology or fibrosis score, suggesting a common signature of hepatitis (Fig. 1, A and B) . Type 2 cytokines were increased in NVH compared with VH (Fig. 1, A and B) and correlated with progression of fibrosis and transition from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as we have reported (25) . Type 3 cytokines were also elevated in patients with advanced liver fibrosis independent of the etiology (Fig. 1, A and B). There was a significant increase of both IL-17A (VH: mean = 680 pg/ml for F0-F2 versus 3754 pg/ml for F3-F4; P = 0.0011; NVH: mean = 370 pg/ml for F0-F2 versus 1719 pg/ml for F3-F4; P = 0.02) and IL-22 (VH: mean = 630 pg/ml for F0-F2 versus 2349 pg/ml F3-F4; P = 0.0017; NVH: mean = 129 pg/ml for F0-F2 versus 1240 pg/ml for F3-F4; P = 0.007) with advanced fibrosis (Fig. 1C) .
To further validate that IL-17A, hereinafter termed IL-17, and IL-22 are common markers of liver fibrosis, we consulted publicly available microarray data comparing moderate and advanced fibrotic livers in two studies on NASH (26) and hepatitis C virus (HCV) (27) , respectively. We performed gene set enrichment analy sis (GSEA) using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases focusing on the top 15 up-regulated pathways between moderate and advanced fibrosis [P < 0.05; false discovery rate (FDR), <25%; fold change (FC), >1.3]. IL-22 signaling was in the top five modulated pathways in both studies (P = 0.000006 NASH and P = 0.0305 HCV; fig. S1 ). Collectively, these results suggest a key role for IL-22 in advanced liver fibrosis.
Type 3 cytokines produced by IHLs promote activation of HSCs
Next, we investigated whether IL-17 and IL-22 enhanced fibrosis by modulating activation of HSCs. We used IHL supernatants from seven patients with advanced fibrosis and high levels of IL-17 and IL-22 to stimulate the human HSC cell line LX2 for 48 hours and then examined the expression of the profibrogenic genes ACTA2 [-smooth muscle actin (-SMA)], COL1A1, TGFB1, and TIMP1 and the chemokines CXCL10 and CCL20 involved in recruitment of type 3 immune cells (Fig. 1D) . We observed high expression of profibrotic genes in stimulated cells (Fig. 1D) . Neutralization of IL-17 (top panels) with anti-IL-17RA, IL-22 (middle panels) with recombinant IL-22 binding protein (rIL-22BP), or TGF- (bottom panels) with anti-TGF- reduced expression of these profibrogenic genes. These results not only validated the previously reported profibrotic function of IL-17A (6-9) but also highlighted a pathogenic role for IL-22 during liver fibrosis through enhanced HSC activation. The profibrogenic functions of IL-17 and IL-22 were dependent on TGF- signaling as neutralization of TGF- inhibited activation of LX2 cells. 
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+ CD4 T cells ( Fig. 2A and fig.  S2A ) (28, 29) . We did not observe substantial changes in the frequency of T H 17 cells in PBMCs ( fig. S2B ) but a significant increase (P = 0.00173) in livers with advanced fibrosis independent of etiology (Fig. 2B) . The frequency of intrahepatic T H 17 cells did not correlate with liver injury measured by serum alanine amino transferase (ALT; fig. S2C ), suggesting that they do not directly contribute to hepatocyte injury but rather enhance fibrosis. Fig. 2C and fig. S2D ). To avoid counting bias, we scanned entire sections and performed automated counting using Visiomorph image acquisition and processing software (Visiopharm). Liver sections were stained with Sirius red to differentiate scar from normal parenchyma and to delineate the region of interest for further analysis ( fig. S3 ). As expected, we observed increased immune infiltrate in fibrotic livers ( S2E ). We then generated tissue heatmaps for IL-17-producing or T H 17 cells to further confirm that type 3 responses were increased in advanced fibrosis and within the fibrotic/scar region (Fig. 2D) . IL-17-producing cells accumulated in the scar region of patients with advanced fibrosis, suggesting a direct fibrogenic role (Fig. 2, G and H) . Similar to our flow cytometry data, there was no correlation between the frequencies of neither IL-17-producing nor T H 17 cells and serum ALT (fig. S2 , F and G).
T regs limit fibrosis through secretion of IL-10 and inhibition of other inflammatory cells including T H 17 cells (18) . Therefore, we examined the frequency of T regs (FOXP3 + CD4 + ) in liver sections (Fig. 2C) . We observed increased numbers of intrahepatic T regs (P = 0.0008, n = 28) in patients with advanced compared with moderate fibrosis (Fig. 2I) . The number of intrahepatic T regs correlated with serum ALT (P = 0.028, r = 0.23, n = 27; fig. S2H ). This suggests that T regs may be recruited to the liver as a mechanism to control ongoing hepatocyte damage. However, it has been proposed that the imbalance between T H 17 and T regs contributes to the pathogenesis of several inflammatory diseases (18) and therefore may influence , and CCL20 after stimulation of LX2 cells with F3-F4 supernatant (n = 7) with or without anti-IL-17RA (50 ng/ml), rIL-22BP (50 ng/ml), or anti-TGF- (1 g/ml). Error bars, means ± SEM. *P < 0.05, **P < 0.01 (ANOVA followed by a post hoc Tukey and Kruskal-Wallis tests were used for multiple and dual comparisons, respectively). + (T H 17)/T reg ratio in liver sections. We observed a tendency (P = 0.103, n = 28) for increased T H 17/T reg ratio in livers with advanced compared with moderate fibrosis (Fig. 2J ). When we delineated the scar versus parenchyma, we observed a significant increase in the T H 17/T reg ratio (P = 0.032, n = 28) in the scar region (Fig. 2K) , suggesting that dysregulation of the type 3 response is associated with enhanced fibrosis.
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Neutrophils and mast cells are the main producers of IL-17 in the liver
Although we observed increased frequencies of T H 17 cells (Fig. 2B) and a dysregulated T H 17/T reg ratio in the livers of patients with advanced fibrosis (Fig 2, J and K) , the majority of IL-17-producing cells in situ were negative for CD4. This suggested that T H 17 cells may not be the main IL-17 producers in the tissue. The majority of IL-17-producing cells had multilobulated nuclei consistent with a neutrophilic phenotype. A second population was always located in the stroma and had a granulocytic morphology, suggesting that they may be mast cells. To characterize these cells, we recruited a new cohort of four patients with moderate and seven with advanced fibrosis (total n = 11). We examined IL-17-producing cells (IL-17 (Fig. 3A) . We observed a significant increase in the density of IL-17-producing cells (P = 0.012) in patients with advanced fibrosis, validating our previous observations (Fig. 3, B and E). The majority of IL-17-producing cells were CD66b + neutrophils, which represented from 48 to 96% of total IL-17-producing cells (Fig. 3 , A and C). IL-17 was stored inside the neutrophils as shown by confocal microscopy ( fig. S4C ). We also found that IL-17-producing neutrophils (IL-17 (Fig 3, A, B , and E to H).
High density of IL-22-producing cells is associated with advanced liver fibrosis
As we observed increased IL-22 levels and IL-22 signaling in our initial screen (Fig. 1, A to C, and fig. S1 ), we investigated whether advanced fibrosis was also associated with a higher density of IL-22-producing cells in situ. We examined the in situ density and localization of IL-22-producing cells by IF in livers from VH (n = 18) and NVH (n = 19; Fig. 4A ). We found higher density of both IL-22-producing cells and IL-22 + CD4 + cells in participants with advanced fibrosis (n = 15) when compared with moderate fibrosis (n = 22), independent of the etiology (Fig. 4, B to D) . Again, the majority of IL-22 producers were not CD4 T cells. They had either a lymphoid or a neutrophilic morphology. Visual inspection suggested that they were neutrophils. This could not be validated in humans due to lack of sufficient tissue, but we were able to validate this neutrophilic phenotype in situ in mice by costaining for IL-22 and Ly6G ( fig. S4, A and B) . Further validation of this neutrophilic phenotype in humans is required.
IL-22-producing cells were located in the parenchyma (mean scar/parenchyma ratio = 0.89) of patients with moderate fibrosis, which suggests a hepatoprotective function in this group (Fig. 4 , E and F) (11) . However, IL-22-producing cells were increasingly located in the scar of patients with advanced liver fibrosis (mean scar/ parenchyma ratio = 1.78; Fig 4, E and F) . The scar/parenchyma ratio was higher for IL-22-producing as compared with IL-17-producing cells (1.78 versus 0.68), suggesting that the IL-22 pathway is associated with fibrosis progression and may play distinct roles during different stages of fibrosis.
IL-22 enhances TGF- signaling in HSCs independent of TGF--RII expression
To define the profibrotic function of IL-22, we stimulated primary human HSCs with either a low (1 ng/ml) or a high (40 ng/ml) dose of IL-22 for 48 hours and investigated whether it will induce HSC activation. HSCs treated with TGF- (2.5 ng/ml, TGF- hi ) were used as a positive control. IL-22 alone was not sufficient to induce HSC activation as demonstrated by comparable mRNA expression levels of ACTA2, COL1A1, TIMP1, and TGFB1 (Fig. 5A ) in treated versus untreated cells. This was validated by low expression of -SMA detected by IF (Fig. 5 , B and C) and Western blot (Fig. 5D) . However, when combined with a low dose of TGF- (0.1 ng/ml, TGF- lo ) that was not sufficient by itself to activate HSCs (6), IL-22 induced activation of HSCs as shown by increased -SMA expression detected by IF (Fig. 5 , B and C) and confirmed at the mRNA (Fig. 5A ) and protein level (Fig. 5D ). To confirm that IL-22 enhances TGF- responses, we repeated our costimulation in the presence of LY2109761, an inhibitor of TGF- signaling, and observed reduced expression of fibrogenic genes in HSCs ( fig. S5, A and B) . As we have previously demonstrated that IL-17 can enhance fibrosis by stabilizing cell surface expression of TGF--RII (6), we examined whether IL-22 would have a similar effect. IL-22 did not alter cell surface expression of TGF--RII (Fig 5E) but enhanced phosphorylation of SMAD2/3 in TGF- lo response in IL-22-stimulated HSCs (Fig. 5F ). These results suggested that IL-22 enhances TGF- responsiveness in HSCs but not through direct action on the TGF- receptor. (Fig. 6A) . We then validated that IL-22 induces phosphorylation of p38 in primary human HSCs (Fig. 6B) . Chemical inhibition of p38 (SB203538, 10 M) in IL-22 + TGF- lo -treated primary HSCs led to reduced HSCs activation as shown by decreased -SMA expression (Fig. 6 , C and D) but had no impact on TGF- hi -treated cells. Treatment of HSCs with SB203538 reduced phosphorylation of SMAD2/3 in response to a suboptimal dose of TGF- and IL-22 stimulation of HSCs (Fig. 6E) . This indicated that IL-22 enhances TGF- signaling in HSCs via activation of the p38/ MAPK pathway. *P < 0.05, **P < 0.01, ***P < 0.001 (ANOVA followed by a post hoc Tukey test).
IL-22 enhances TGF- signaling in
IL-22 signaling is not required for control of hepatic inflammation during chronic liver injury
To characterize the function of IL-22 during chronic liver injury, we treated 6-to 8-week-old male and female (matched ratio between groups) IL-22RA1 KO C57BL/6 mice and wild-type (WT) littermates with either carbon tetrachloride (CCl 4 ) or thioacetamide (TAA) for 12 weeks to model high and mild hepatic inflammation, respectively. At 12 weeks, we observed increased liver size, liver/ body mass ratio, and splenomegaly after CCl 4 treatment ( fig. S7 , A to C). Serum ALT was also increased in both models (figs. S7D and S8B). There was no significant difference in serum ALT levels between IL-22RA1 KO and WT treated mice, suggesting that IL-22 does not exert hepatoprotective functions in this chronic injury model as previously reported during acute injury (11) . We also observed increased frequency of activated T regs (CD39 + CTLA4 + ) after injury in both IL-22RA1 KO and WT mice ( fig. S9, A and B) and a positive correlation between T regs and serum ALT similar to our human data ( fig. S9C ). The frequency of T regs also correlated with the hydroxyl-proline liver content ( fig. S9D ) suggesting a profibrotic function of these cells, as previously reported (22, 23) .
IL-22 signaling enhances liver fibrosis during chronic hepatic injury
Next, we sought to determine whether lack of IL-22 signaling in vivo during chronic liver injury will affect fibrosis. WT mice exhibited overt liver fibrosis that was reduced in IL-22RA1 KO. Expression levels of profibrogenic genes col1a1, timp1, tgfb1, and loxl2 as well as genes associated with activated HSCs acta2 and tgfbrii were reduced in the liver of IL-22RA1 KO compared with WT in CCl 4 and TAA models (Fig. 7, A and G, and fig. S8A ). We confirmed this phenotype at the protein level as shown by decreased expression of -SMA, desmin, and collagen type I deposition (Fig. 7, B and D to G) measured by IF, Sirius red staining, and hydroxy-proline liver content, respectively. WT showed severe bridging fibrosis and thick collagen network as compared with the IL-22RA1 KO (Fig. 7D ). This correlated with the reduced expression of loxl2 (Fig. 7A) . We observed 40% reduction in collagen deposition in IL-22RA1 KO compared with WT after both CCl 4 and TAA treatment (Fig. 7, E  and F, and fig. S8, C and D) . We also observed significant increase (P < 0.0001) of IL-22 in both WT and IL-22RA1 KO (Fig. 7A and  fig. S10A ). Last, we confirmed that IL-22-producing cells were present in the liver of treated mice by IF. In both WT and IL-22RA1 KO, IL-22-producing cells were increased in the liver and located in close proximity of HSCs (Fig. 7C) . As described above, we observed two morphologically distinct IL-22-producing cellular populations of either neutrophilic or lymphocytic morphology. We further characterized the lymphocytic IL-22-producing cells by flow cytometry and found that the majority were CD3-negative, NK1.1 + Nkp46 + RORt + cells, suggesting that they may be ILC3 (fig. S10, A and B) (32) . There were no major differences in the distribution of immune cell subsets between IL-22RA1 KO and WT, suggesting that the reduction in fibrosis is due to the absence of IL-22 signaling and not due to alterations in inflammatory cell frequencies.
Inhibition of the type 3 cytokines, IL-22 and IL-17, with AHR and RORt antagonists reduces liver fibrosis
RORt and aryl hydrocarbon receptor (AHR) are master regulators of type 3 responses (33) . RORt is important for the differentiation of type 3 immune cells and controls production of IL-17, whereas production of IL-22 is largely dependent on expression of the TF AHR (33) (34) (35) . These two pathways have become interesting targets for therapeutic intervention in various inflammatory conditions (36) . Thus, we investigated whether inhibition of IL-22 and IL-17 production in vivo could reduce liver fibrosis. WT mice were treated for 4 weeks with CCl 4 or TAA. At 2 weeks, mice started receiving daily intraperitoneal injections of either the AHR antagonist (CH-223191, 10 mg/kg) or the RORt antagonist (GSK805, 10 mg/kg), whereas control mice received vehicle (Fig. 8A) . Treatment was well tolerated and we did not observe any toxicity in the heart, lung, or kidney by histological analysis (fig. S11) . We observed reduction in the mRNA levels of the profibrogenic genes col1a1, acta2, timp1, tgfb1, and loxl2 in the liver (Fig. 8B and fig. S12A ). We then quantified the desmin-positive area and the liver density of IL-22 + cells. Mice treated with either the AHR or RORt antagonist had a significant reduction of both desmin-positive area (closed circles) and the liver density of IL-22
+ cells (open circles; Fig. 8C ). Intrahepatic neutrophils and IL-17 + cells were also reduced in mice treated with the RORt antagonist ( fig. S13) . Furthermore, collagen deposition in the liver was reduced as shown by Sirius red and hydroxy-proline assays (Fig. 8, D to F, and fig. S12 , B to D), respectively. In conclusion, modulation of IL-22-and IL-17-producing cells using AHR and RORt antagonists during chronic liver injury reduced the degree of liver fibrosis (Fig 8G) .
DISCUSSION
We demonstrated that type 3 inflammation is a major driver of fibrosis during chronic liver injury. We observed dysregulation of type 3 responses in fibrotic livers, with increased production of IL-17 and IL-22. This was confirmed by gene signatures in publicly available microarray data. We have also identified neutrophils and mast cells as the main producers of IL-17 in situ. Neutrophils and mast cells are implicated in the progression of fibrosis in many organs due to their capacity to secrete profibrogenic factors such as reactive oxygen species, LOXL2 TGF-, and platelet-derived growth factor (37) . IL-17-producing neutrophils were already reported to be profibrogenic during experimental hepatitis and in one cohort of HCV-infected patients (30, 38) . Mast cells have been associated with liver fibrosis progression, interact with HSCs, and are one of the "core" fibrogenic populations in the body (39) . IL-17-producing mast cells are associated with disease progression in rheumatoid arthritis and psoriasis (40, 41) , suggesting that they may have a similar function in the liver. IL-17-producing cells accumulated in the scar region independent of the etiology, suggesting an active role in the fibrogenic process (Fig. 2, G and H) . Although T H 17 cells were not the principal source of IL-17 in situ, they may enhance recruitment of innate effectors through induction of proinflammatory chemokines by endothelial cells (7) . It is also possible that T H 17 cells are active early during inflammation but become inhibited in situ with advanced fibrosis.
We observed increased numbers of FOXP3 hi CD4 + T regs in livers with advanced fibrosis and frequency of T regs correlated with elevated serum ALT levels (Fig. 2G and fig. S2H ). This is consistent with observations in mice (24) and humans (23) suggesting that T regs are recruited to the liver to regulate ongoing inflammation and damage. However, distribution of T regs was not uniform because we observed dysregulation of the T H 17/T reg ratio in the scar compared with normal parenchyma in patients with advanced fibrosis (22, 23) . Because Scale bars, 100 m. Error bars, means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (ANOVA followed by a post hoc Tukey and Kruskal-Wallis tests were used for multiple and dual comparisons, respectively).
TGF- is essential for the differentiation of both T H 17 and T regs (42) and given the reported plasticity between these two cell subsets (19) , it is possible that liver inflammation mediated by TNF-, IL-1, and IL-6 indirectly promotes differentiation of T regs into T H 17 cells and therefore promotes fibrosis. TGF- may also favor inhibition of T H 17 cells by T regs during chronic liver injury (43) . This may explain our inability to detect IL-17 production by T H 17 cells in situ despite their high frequency. It is also possible that T regs accelerate to liver activates the p38/ MAPK pathway increasing phosphorylation of SMAD3 and therefore HSCs activation. Scale bars, 100 m. Error bars, means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (ANOVA followed by a post hoc Tukey and Kruskal-Wallis tests were used for multiple and dual comparisons, respectively).
fibrosis progression through inhibition of the antifibrogenic function(s) of NK cells (22, 23) . IL-22 was the cytokine most significantly up-regulated in advanced fibrosis in clinical samples ( Fig. 1 and fig. S1 ). Whether IL-22 exerts pro-or antifibrogenic functions on HSCs is controversial (44) . Some studies reported that in vitro IL-22 induces senescence of HSCs through induction of p21 or -catenin after 24 hours but protects against apoptosis (14, 45) . In contrast, our RNA-seq analysis (at 48 hours) demonstrated that IL-22 did not induce senescence but rather proliferative and antiapoptotic signatures and degradation of p21 in primary HSCs (fig. S6 ). This is consistent with reports in the pancreas and liver (46, 47) . This can be explained by different stimulation times. It is also possible that increased proliferation of HSCs in response to IL-22 may cause them to reach cellular confluence by 24 hours and up-regulate cell cycle arrest molecules such as p21/p53 (48) that are then degraded by 48 hours. We also demonstrated that IL-22 by itself did not activate HSCs but it enhances TGF- signaling in a p38-dependent mechanism (Fig. 5) . Other studies have reported direct activation of pancreatic stellate cells or LX2 cells by IL-22 (46, 47) . However, they used higher IL-22 concentrations (100 ng/ml versus 1 and 40 ng/ml) and reported activation of different sets of genes. In our hands, IL-22 + TGF- lo -treated HSCs exhibited a gene signature associated with MEF-2 activation (Fig. 6A ). MEF-2 is a p38-dependent TF important for activation of HSCs and regulation of TGF- signaling (31, 49) . This may reflect a dual and concordant effect of IL-22 and TGF- that may promote optimal tissue repair under normal or acute injury conditions, but elevated levels and sustained signaling may enhance the pathogenic effects of both cytokines during chronic injury. Last, lack of IL-22 signaling in vivo led to reduced fibrosis and decreased activation of HSCs (Fig. 7B) . IL-22-producing cells were found in proximity of HSCs, suggesting that they contribute to their activation by enhancing TGF- signaling (Fig. 7C) . In vivo, most IL-22-producing lymphocytes were CD3-negative NK1.1 + NKp46 + cells expressing high levels of RORt ( fig. S10 ), suggesting that they are ILC3s (50) . These results differ from Kong et al. (14) that used a liver-specific transgenic mouse model, where IL-22 levels were high and IL-22 signaling was most likely directed to hepatocytes that might not be physiological. We demonstrated that, in humans and mice, IL-22-producing cells were located in the scar. This suggests that the localization and cellular targets of IL-22 (epithelium versus fibroblast) may shift the balance from an anti-to a profibrogenic/inflammatory function.
In conclusion, we demonstrated a profibrogenic function of IL-22 through enhancement of TGF- signaling in a p38/MAPKdependent mechanism. Our data suggest that dysregulation of type 3 inflammation during chronic liver injury is one of the key mechanisms of fibrogenesis in humans, and we identified neutrophils and mast cells as major producers of IL-17 in this setting. Morphological examination and flow cytometry suggest that IL-22 is also produced by multiple sources, potentially by neutrophils and ILC3 but further characterization is needed. Additional research examining the kinetics of recruitment and/or activation of the different IL-17-and IL-22-producing cells in the liver after injury is essential. Similarly, the role of T regs in regulating type 3 response during liver fibrosis is not well understood. Last, in acute liver injury, lack of IL-22BP, which leads to abnormal IL-22 signaling, induces pathological inflammatory responses and necrosis (51) . The in vivo regulation of IL-22 by IL-22BP during chronic liver injury remains an open question and should be examined in future studies. We have provided a proof of concept that targeting IL-17 and IL-22 with antagonists of TFs such as AHR and RORt can limit liver fibrosis, but additional research with prolonged treatment and different treatment regimens applied during various stages of liver injury should be tested to validate the potential use of this strategy in treatment of liver fibrosis.
MATERIALS AND METHODS
Study design
The goal of this study was to investigate the role of the type 3 cytokines IL-17 and IL-22 in liver fibrosis. We used clinical samples (IHLs and FFPE liver sections) from participants undergoing diagnostic liver biopsies at the Centre hospitalier de l'Université de Montréal (CHUM) with different liver disease etiologies to identify, quantify, and define localization of IL-17-and IL-22-producing cells in the liver using flow cytometry and advanced imaging techniques. Samples were blinded for the degree of liver fibrosis throughout the initial immunological analysis and were all scored using the METAVIR score by an independent pathologist then unblinded at the final analysis. The fibrogenic role of IL-17 and IL-22 was confirmed in vitro using primary HSC and in vivo using IL-22RA KO mice and pharmacological inhibitors. The number of independent experiments and inclusion of individuals are described in the figure legends and in table S1. Data points were excluded only in the case of technical or processing errors that caused poor quality control of the sample.
Study participants
Peripheral blood and fresh and FFPE human liver specimens were obtained from participants after informed consent. This study was approved by the institutional ethics committee (protocol SL09.228) and performed in accordance with the Declaration of Helsinki. Participants' clinical characteristics and demographics are listed in table S1.
Mice
All experimental procedures were approved by the Institutional Animal Care and Use Committee. IL-22RA1 KO were rederived using sperm from the Mutant Mouse Resource and Research Center (University of California, Davis, CA) and C57/BL6 mice from the Jackson laboratory (Sacramento, CA). Six-to 8-week-old male and female IL-22RA1 KO and WT littermates were treated with CCl 4 (Sigma-Aldrich, Oakland, ON) resuspended in corn oil [0.5 ml/kg two intraperitoneal (i.p.) injections per week], TAA (Sigma-Aldrich) in phosphate-buffered saline (PBS) (200 mg/kg i.p., three times per week), or vehicle (corn oil or PBS). For the therapeutic intervention, WT mice were placed on CCl 4 (0.5 ml/kg i.p., twice per week) or increasing doses of TAA [three i.p. injections per week at 100 mg/kg i.p. (week 1), 200 mg/kg (week 2), and 300 mg/kg (weeks 3 and 4)] for 4 weeks and treated from weeks 2 to 4 daily with either the AHR antagonist CH-223191 (10 mg/kg i.p. in corn oil) or the RORt antagonist GSK805 (10 mg/kg i.p. in corn oil) using vehicle as a control. Mice were terminally euthanized with sodium pentobarbital (400 mg/kg) and 2% xylocaine. All animals were housed under specific pathogen-free conditions.
Immunofluorescent staining and image analysis FFPE sections were deparaffinized and dehydrated. Antigen retrieval was performed using sodium citrate (pH 6) for 10 min at high temperature and pressure. Sections frozen in optimal cutting temperature (OCT) compound were stored at −80°C and warmed up to room temperature. All sections were blocked with either human serum in 1% bovine serum albumin (BSA) in PBS or in serum-free blocking agent (Dako, Santa Clara, CA). To reduce autofluorescence, sections were incubated in 0.1 mM glycine for 10 min, then incubated with primary antibodies overnight in 1% BSA, 0.1% Triton X-100 in PBS at 4°C, and then washed five times for 5 min in PBS, 0.1% Triton X-100 solution. Secondary antibody incubation was performed in 1% BSA, 0.1% Triton X-100 in PBS solution at room temperature for 1 hour. Sections were mounted in Slowfade Gold mounting media with 4′,6-diamidino-2-phenylindole (Thermo Fisher Scientific, Fremont, CA, USA).
Statistical analysis
All data were analyzed using GraphPad Prism 6 and 7 for generation of heatmap (GraphPad Software, La Jolla, CA). Differences between two groups were determined by Mann-Whitney, whereas differences between groups were determined by analysis of variance (ANOVA), followed by Tukey post hoc test. Kruskal-Wallis tests were used when group sizes were too different and if the data did not meet the assumption of homogeneity of variance. Correlations were tested using Spearman's rank correlation.
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